Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
Marc A RiedlHenriette FarkasEmel Aygören-PürsünFotis PsarrosDaniel F SoteresMaria StaevskaMauro CancianDavid HaginDaisuke HondaIsaac MelamedSinisa SavicMarcin StobieckiPaula J BusseEunice Dias de CastroNancy Agmon-LevinRichard GowerAharon KesselMarcin KurowskiRamon LleonartVesna Grivcheva PanovskaH James WednerPaul K AudhyaJames HaoMatthew IversonMichael D SmithChristopher M YeaWilliam R LumryAndrea ZanichelliJonathan A BernsteinMarcus MaurerDanny M Cohnnull nullPublished in: The New England journal of medicine (2024)
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).
Keyphrases